Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Brain Neoplasms 2Turcot syndrome 1Neoplasms 1Medulloblastoma 1Glioma 1Familial ependymoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1

Interventions

Magnetic Resonance Spectroscopy 14Temozolomide 10Specimen Handling 10X-Rays 8Radiotherapy 7Biopsy 7Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6trametinib 4ulixertinib 3olaparib 3larotrectinib 3erdafitinib 3dabrafenib 3Radiotherapy, Intensity-Modulated 3Nivolumab 3tipifarnib 2selpercatinib 2pembrolizumab 2palbociclib 2niraparib 2ivosidenib 2ensartinib 2atezolizumab 2abemaciclib 2Surveys and Questionnaires 2Radiation 2Proton Therapy 2Lomustine 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Glioma × Diffusion Tensor Imaging × Clear all
NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡